TickerTalks
Browse all tickers →
TickerTalks›$PDSB
PDPDSB

PDS Biotechnology Corporation

$PDSB·$45M·Biotechnology·Healthcare
$0.81-4.4%YTD+6.3%1Y-30.0%
Price updated 1h ago
PDPDSB
$PDSBPDS Biotechnology Corporation
$0.81-4.36%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PDSB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PDSB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-18

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

A struggling immuno-oncology biotech has attracted a well-known biotech founder as its lead financier — the story has been redrawn.

PDS Biotechnology is a clinical-stage immuno-oncology company developing a novel T-cell activation platform aimed at solid tumours. It has spent months trading like a listing-compliance story, and a specific new financing has just rewritten the equity picture.

  • The financial screen is what one would expect at this stage: reported revenue is zero, gross margin is zero as a result, and free-cash-flow yield is deeply negative — a business dependent on capital raises to fund clinical work.
  • A concrete corporate catalyst has landed: management has announced an initial closing of a large private-placement financing led by a well-known biotech-and-medical-technology founder, alongside an appointment tied to that investor — a specific validation signal rather than a routine capital raise.
  • Corporate housekeeping has been busy: a material agreement was terminated in one recent filing, with an officer or director change alongside a Reg-FD disclosure, and traders have been active in call options — the classic mix of setup that follows a headline-financing announcement.

There is no meaningful near-term earnings-driven catalyst; the shares move on further disclosure of the private-placement's use of proceeds, on any updated clinical-trial roadmap, and on how the new financier engages with the pipeline strategy.

What to watch: Further disclosure of the private-placement's use of proceeds and any updated clinical-trial roadmap from the new financier's team, plus follow-on financing tranches. Any specific data readout on the lead immuno-oncology programme would be a step-change catalyst.

On the calendar: Next Phase-programme readout — date pending

no x sentiment

Read the AI verdict on $PDSB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PDSB.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

Top industry ETF

$IBBiShares Biotechnology ETF
+22.1%YTD
+42.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-35.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-30.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-7.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.18$-0.13-38.5%
Q1 2026May 13, 2026$-0.13$-0.15+13.3%
Q4 2025Mar 30, 2026$-0.14$-0.20+30.0%
Q3 2025Nov 13, 2025$-0.19$-0.21+9.5%
Next earningsThu, Nov 12·consensus EPS $-0.11

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.18$-2.8M
Q1 FY26$0———$-0.13$-4.4M
Q4 FY25$0———$-0.14$-3.7M
Q3 FY25$0———$-0.19$-5.9M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.3M$11.3M – $11.3M-$0.47-$0.47 – -$0.472
FY27$23.1M$23.1M – $23.1M-$0.30-$0.30 – -$0.302
FY28$3.8M$3.8M – $3.8M-$0.23-$0.29 – -$0.162
FY29$93.4M$93.4M – $93.4M$0.50$0.50 – $0.501
FY30$196.9M$196.9M – $196.9M$1.51$1.51 – $1.511

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+61.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+0.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 54.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today34.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.455-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedSep 148-K — Item 1.02: Agreement terminated · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

PDS Biotechnology Corporation (PDSB) filed a multi-item 8-K on September 12, 2026, disclosing the termination of a material agreement (Item 1.02), an officer or director change (Item 5.02), a Reg FD disclosure (Item 7.01), and another material event (Item 8.01). The combination of a contract termination with simultaneous personnel and other-event disclosures strongly suggests a significant strategic restructuring or clinical program discontinuation at this clinical-stage immunotherapy company. The excerpt shows only the cover page; the breadth of concurrent items makes this filing high-priority for review.

8-KMaterial agreementSep 88-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K on September 7, 2026, disclosing a material definitive agreement (Item 1.01) alongside unregistered equity sales (Item 3.02) and a Reg FD disclosure (Item 7.01). For a clinical-stage biotech, this combination typically signals a new PIPE or convertible note financing where the agreement terms and share issuance occur simultaneously. The excerpt shows only the cover page with no financial terms or counterparty identified.

8-KMaterial agreementSep 48-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K on August 31, 2026, disclosing both a material definitive agreement (Item 1.01) and the creation of a direct financial obligation (Item 2.03). This combination is characteristic of a new debt instrument or credit facility being drawn — the agreement establishes terms and Item 2.03 confirms the obligation is live. For a cash-constrained clinical-stage biotech, this represents a material financing event.

8-KRestructuring / exit costsAug 258-K — Item 2.05: Restructuring / exit costs · Item 5.02: Officer or director change
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K on August 21, 2026, disclosing both restructuring or exit-related costs (Item 2.05) and an officer or director change (Item 5.02). This combination strongly suggests a corporate restructuring or workforce reduction accompanied by a leadership change — consistent with a company under financial stress or executing a clinical pipeline pivot. No financial details are available from the cover-page-only excerpt.

8-KOfficer or director changeAug 198-K — Item 5.02: Officer or director change
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K reporting an officer or director change (Item 5.02) effective August 13, 2026; the excerpt contains only the cover page with no details on the specific individual or role. This is a routine governance disclosure for the clinical-stage immunotherapy company.

8-KCharter amendmentAug 148-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K on August 10, 2026, reporting both bylaw/charter amendments (Item 5.03) and the results of a shareholder vote (Item 5.07). Charter amendments at a clinical-stage biotech often accompany authorized share increases to support active financing programs. No specific details are visible from the cover-page-only excerpt, but the disclosure is material given PDSB's track record of equity-linked financing activity.

8-KPress release / Reg FDAug 118-K — Item 7.01: Press release / Reg FD
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K under Item 7.01 (Reg FD) on August 11, 2026, furnishing investor presentation materials; the excerpt shows only the cover page. This is a routine compliance disclosure accompanying an investor conference appearance or data presentation for the clinical immunotherapy company.

8-KListing / delisting noticeJul 318-K — Item 3.01: Listing / delisting notice
AI summary

PDS Biotechnology Corporation (PDSB) filed an 8-K on July 30, 2026, disclosing a notice of delisting or failure to satisfy a Nasdaq Capital Market continued listing requirement (Item 3.01). Delisting notices are materially adverse events that trigger a cure period during which the company must remediate the deficiency — typically minimum bid price, equity value, or market capitalization. The specific violated requirement is not visible in the excerpt, but the disclosure itself signals acute financial stress at this pre-revenue clinical-stage biotech.

+ 24 other (4 routine 8-Ks · 3 earnings 8-Ks · 2 10-Qs · 2 EFFECTs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directorsglobenewswire.com·5d agoTraders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)defenseworld.net·11d agoPDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorksglobenewswire.com·11d agoPDS Biotech Reports Second Quarter 2026 Financial Resultsglobenewswire.com·37d agoPDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Programbenzinga.com·39d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $PDSB on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport